Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 4, 2009, Pages 197-203

  Leey, Julio A ^a   McCabe, Steve ^b   Koch, Jennifer A ^c   Miles, Toni P ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

bleeding; cost effectiveness; decision analysis; pharmacogenetics; stroke; warfarin

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG EFFICACY; GENOTYPE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL EMBOLISM; PHARMACOGENETICS; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 70349111152     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.07.002     Document Type: Article

References (18)

1. Fuster V., Rydén L.E., Cannom D.S., et al., the Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation of the American College of Cardiology, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50:562]. J Am Coll Cardiol. 48 (2006) 854-906
2. Landefeld C.S., and Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 87 (1989) 144-152
3. Fanikos J., Grasso-Correnti N., Shah R., et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 96 (2005) 595-598
4. Leigh J.P., and White R.H. An economic model for adverse events and costs for oral anticoagulants used for atrial fibrillation. Curr Med Res Opin. 23 (2007) 2071-2081
5. Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 53 (2007) 1199-1205
6. Gage B.F., and Lesko L.J. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25 (2008) 45-51
7. Sanderson S., Emery J., and Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genet Med. 7 (2005) 97-104
8. Anderson J.L., Horne B.D., Stevens S.M., et al., the Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (2007) 2563-2570
9. Caraco Y., Blotnick S., and Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther. 83 (2008) 460-470
10. Richardson W.S., Detsky A.S., and the Evidence-Based Medicine Working Group. Users′ guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients?. JAMA. 273 (1995) 1610-1613
11. O'Brien C., and Gage B.F. Costs and effectiveness of ximela-gatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 293 (2005) 699-706
12. Hylek E., Evans-Molina C., Shea C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007) 2689-2696
13. Campos-Outcalt D. Personalized medicine: The promise, the reality. J Fam Pract. 56 (2007) 621-626
14. Klein T.E., Altman R.B., Eriksson N., et al., International Warfarin Pharmacogenetic Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 360 (2009) 753-764
15. You J.H., Chan F.W., Wong R.S., and Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis. Thromb Haemost 92 (2004) 590-597
16. Eckman M.H., Rosand J., Greenberg S.M., and Gage B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 150 (2009) 73-83
17. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 151 (2006) 713-719
18. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 358 (2008) 999-1008